{"id":163,"date":"2024-01-10T22:00:00","date_gmt":"2024-01-10T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=163"},"modified":"2025-09-02T13:41:53","modified_gmt":"2025-09-02T13:41:53","slug":"china-original-asset-gsk-and-aiolos-bio-enters-a-1-4-billion-usd-acquisition-for-tslp-abs-aio-001-shr-1905-from-hengrui","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/163.html","title":{"rendered":"[China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for  TSLP Abs AIO-001 (SHR-1905 from Hengrui)"},"content":{"rendered":"\n<p>Announced Date: 2024-01-09 (January 09, 2024)<\/p>\n\n\n\n<p>Buyer: GSK plc (GSK)&nbsp;<\/p>\n\n\n\n<p>Seller: Aiolos Bio, Inc. (Aiolos)&nbsp;<\/p>\n\n\n\n<p>Key Asset: AIO-001 (SHR-1905 from Hengrui)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Monoclonal antibody<\/p>\n\n\n\n<p>Asset Target: thymic stromal lymphopoietin (TSLP)\u00a0<\/p>\n\n\n\n<p>Potential Indication: asthma, potential additional indications including chronic rhinosinusitis with nasal polyps.<\/p>\n\n\n\n<p>Current Stage: phase II-ready<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Transaction and Payment Detail:<\/p>\n\n\n\n<p>GSK will acquire Aiolos,  Share holder of  Aiolos Bio will be eligible to receive:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;$1 billion,<\/p>\n\n\n\n<p>Certain success-based regulatory milestone payments up to $400 million.<\/p>\n\n\n\n<p>Total up to $1.4 billion.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Hengrui.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-agreement-to-acquire-aiolos-bio\/\">GSK enters agreement to acquire Aiolos Bio | GSK<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-01-09 (January 09, 2024) Buyer: GSK plc (GSK)&nbsp; Seller: Aiolos Bio, Inc. (Aiolos)&nbsp; Key &hellip; <a title=\"[China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for  TSLP Abs AIO-001 (SHR-1905 from Hengrui)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/163.html\"><span class=\"screen-reader-text\">[China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for  TSLP Abs AIO-001 (SHR-1905 from Hengrui)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-163","post","type-post","status-publish","format-standard","hentry","category-china-original-asset"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=163"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/163\/revisions"}],"predecessor-version":[{"id":166,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/163\/revisions\/166"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}